Laboratory Corporation of America Holdings
NYSE:LH
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
191.8992
246.22
|
Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Intrinsic Value
The intrinsic value of one LH stock under the Base Case scenario is 259.89 USD. Compared to the current market price of 239.67 USD, Laboratory Corporation of America Holdings is Undervalued by 8%.
The Intrinsic Value is calculated as the average of DCF and Relative values:
Valuation Backtest
Laboratory Corporation of America Holdings
Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.
Start backtest now and learn if your stock is truly undervalued or overvalued!
Stock is trading at its lowest valuation over the past 5 years.
To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.
The backtest for LH cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.
Fundamental Analysis
Economic Moat
Laboratory Corporation of America Holdings
Select up to 3 indicators:
Select up to 3 indicators:
Months
Months
Months
Months
Select up to 2 periods:
Laboratory Corporation of America Holdings, commonly referred to as LabCorp, has established itself as a leader in the biomedical testing and diagnostics industry. Founded in 1971, the company operates with a mission to improve health and improve lives by providing critical laboratory services to healthcare providers, pharmaceutical companies, and patients. LabCorp offers a comprehensive range of tests, encompassing everything from routine blood work to complex genomic testing. This diverse portfolio positions LabCorp to benefit from the growing demand for diagnostic services, particularly as healthcare continues to evolve toward precision medicine and personalized care. For investors, LabC...
Laboratory Corporation of America Holdings, commonly referred to as LabCorp, has established itself as a leader in the biomedical testing and diagnostics industry. Founded in 1971, the company operates with a mission to improve health and improve lives by providing critical laboratory services to healthcare providers, pharmaceutical companies, and patients. LabCorp offers a comprehensive range of tests, encompassing everything from routine blood work to complex genomic testing. This diverse portfolio positions LabCorp to benefit from the growing demand for diagnostic services, particularly as healthcare continues to evolve toward precision medicine and personalized care.
For investors, LabCorp's strategic initiatives and strong financial performance paint a compelling picture. The company has successfully expanded through a series of acquisitions, enhancing its capabilities and market reach. With a focus on innovation, LabCorp has invested heavily in advanced technologies and digital solutions to streamline operations and enhance customer experience. As the healthcare landscape shifts toward value-based care, LabCorp is well-positioned to capture market share and drive revenue growth. With a history of consistent earnings and a commitment to shareholder value, LabCorp represents a potentially attractive investment for those looking to engage in the evolving healthcare sector.
Laboratory Corporation of America Holdings, commonly known as LabCorp, is a prominent life sciences company that provides a wide array of laboratory services and diagnostics. The core business segments of LabCorp can typically be categorized as follows:
-
Diagnostic Laboratory Services: This segment encompasses a broad range of laboratory testing services used in clinical diagnosis. It includes routine tests (like blood tests and urinalysis), specialties (such as molecular diagnostics, genetic testing), and esoteric testing. The diagnostic services are utilized by healthcare providers to aid in the diagnosis and management of diseases.
-
Drug Development Services: Through its Covance subsidiary, LabCorp offers comprehensive drug development services. This includes preclinical and clinical research services, which support pharmaceutical and biotechnology companies in the development and approval of new therapies. This segment plays a crucial role in coordinating clinical trials and ensuring that new medications are tested effectively.
-
Genetic Testing and Genomics: LabCorp provides extensive genetic testing services that assess predisposition to certain diseases, hereditary conditions, and pharmacogenomics (how an individual’s genetic makeup affects their response to drugs). This segment has been gaining importance as personalized medicine becomes more prevalent.
-
Specialty Testing: LabCorp offers specialty testing services that address specific medical conditions or areas of health concern, such as oncology, endocrinology, infectious diseases, and more. These tests often require advanced technology and specific expertise.
-
Pathology Services: In this segment, LabCorp provides diagnostic services that involve the examination of tissues and cells, often post-surgery. Pathologists analyze samples to provide crucial information for the diagnosis and treatment of various diseases, especially cancer.
-
Health and Wellness Testing: LabCorp offers a range of health and wellness testing services that can be conducted on consumers directly. These may include tests for cholesterol levels, vitamin D levels, and other health markers that individuals can request without a physician's order.
These core segments enable LabCorp to have a diversified business model, which not only enhances its revenue streams but also positions it strategically in the rapidly evolving healthcare landscape. The company focuses on innovation, expanding its service offerings, and leveraging advancements in technology, such as artificial intelligence and automation, to improve diagnostic accuracy and efficiency.
Laboratory Corporation of America Holdings (LabCorp) possesses several unique competitive advantages that bolster its position in the diagnostic laboratory services industry:
-
Comprehensive Test Menu: LabCorp offers a broad range of diagnostic tests, including clinical laboratory services, genetic testing, and pathology services. This wide array of offerings allows it to serve a diverse clientele and meet various clinical needs.
-
Advanced Technology and Innovation: LabCorp invests significantly in technology and innovation, including automation and molecular diagnostics. This commitment enhances efficiency, reduces turnaround times, and improves test accuracy, which is crucial in a highly competitive market.
-
Strong Brand Reputation: With decades of experience, LabCorp has established itself as a trusted name in laboratory services. This brand loyalty can lead to stronger relationships with healthcare providers and patients, giving it an edge over newer or less well-known competitors.
-
Extensive Network and Scale: LabCorp has an extensive network of laboratories and patient service centers across the U.S. This geographic reach allows for increased convenience for patients and healthcare providers and helps spread fixed costs over a larger volume of services.
-
Strategic Partnerships and Collaborations: The company often engages in strategic partnerships with pharmaceutical companies, healthcare providers, and research institutions. These collaborations can enhance service offerings, improve market access, and support innovation.
-
Strong Financial Position: LabCorp's robust financial performance grants it the ability to invest in research and development, acquisitions, and technology upgrades, keeping it ahead of competitors and positioning it well for growth.
-
Commitment to Quality and Compliance: LabCorp is dedicated to maintaining high standards in quality assurance and regulatory compliance. Its adherence to rigorous quality control measures helps manage risks and build trust with clients and partners.
-
Data Analytics Capabilities: Leveraging its extensive data from diagnostic testing, LabCorp can offer valuable insights and analytics to healthcare providers. This data-driven approach allows LabCorp to differentiate itself by providing enhanced value to its clients.
-
Diverse Revenue Streams: By serving a broad market, including individual patients, hospitals, and pharmaceutical companies, LabCorp mitigates the risk associated with dependence on a single revenue source, providing stability and growth potential.
These competitive advantages help LabCorp maintain a strong position in the laboratory services sector, allowing it to adapt to industry trends, address customer needs, and foster long-term growth.
Laboratory Corporation of America Holdings (LabCorp) faces several risks and challenges in the near future, including:
-
Regulatory Changes: The healthcare and laboratory industries are subject to stringent regulations. Changes in regulations, especially surrounding reimbursement models, billing practices, and compliance requirements, could impact LabCorp's operations and profitability.
-
Market Competition: The laboratory testing market is competitive, with numerous players ranging from small specialized labs to large healthcare systems. Increased competition could lead to pricing pressures and market share losses.
-
Technological Advancements: The rapid pace of technological innovation presents both opportunities and threats. LabCorp must continue to invest in and adapt new technologies to maintain competitive advantage. Failure to do so may result in obsolescence.
-
Economic Factors: Economic downturns can affect healthcare spending. During such times, patients may delay testing, and insurance companies may tighten coverage, impacting LabCorp’s revenues.
-
Supply Chain Disruptions: Global supply chain issues can affect the availability of laboratory supplies and equipment, leading to operational delays and increased costs.
-
Labor Shortages: The healthcare industry is facing a shortage of skilled labor, including phlebotomists and laboratory technicians. Difficulty in recruiting and retaining qualified personnel can hamper service delivery.
-
Cybersecurity Risks: The sensitivity of patient data makes LabCorp a target for cyberattacks. A breach could lead to significant legal and financial repercussions as well as damage to the company’s reputation.
-
Changes in Consumer Behavior: As patients become more empowered and informed, they may seek alternative testing options, including home testing kits and direct-to-consumer testing services, which could disrupt traditional laboratory models.
-
Health Crises and Pandemics: Ongoing or future health crises, such as pandemics, can cause unpredictable fluctuations in demand for laboratory services. While they may initially increase demand, they can also strain resources and lead to operational challenges.
-
Litigation Risks: Like any company in the healthcare sector, LabCorp may face legal challenges related to malpractice claims, patent disputes, or regulatory violations, which could lead to financial losses and reputational damage.
Addressing these risks requires strategic foresight, investment in innovation, strong regulatory compliance, and robust risk management practices.
Revenue & Expenses Breakdown
Laboratory Corporation of America Holdings
Balance Sheet Decomposition
Laboratory Corporation of America Holdings
Current Assets | 4.9B |
Cash & Short-Term Investments | 1.5B |
Receivables | 2.2B |
Other Current Assets | 1.2B |
Non-Current Assets | 13.7B |
Long-Term Investments | 16.9m |
PP&E | 3.1B |
Intangibles | 10B |
Other Non-Current Assets | 612.6m |
Current Liabilities | 3.4B |
Accounts Payable | 660.9m |
Accrued Liabilities | 941.8m |
Other Current Liabilities | 1.8B |
Non-Current Liabilities | 7B |
Long-Term Debt | 5.4B |
Other Non-Current Liabilities | 1.6B |
Earnings Waterfall
Laboratory Corporation of America Holdings
Revenue
|
12.7B
USD
|
Cost of Revenue
|
-9.2B
USD
|
Gross Profit
|
3.5B
USD
|
Operating Expenses
|
-2.4B
USD
|
Operating Income
|
1.1B
USD
|
Other Expenses
|
-701.1m
USD
|
Net Income
|
435.5m
USD
|
Free Cash Flow Analysis
Laboratory Corporation of America Holdings
USD | |
Free Cash Flow | USD |
Labcorp's Q3 revenue rose to $3.3 billion, a 7.4% increase, driven by 8.9% growth in Diagnostics and strong Central Laboratory performance. Adjusted EPS of $3.50 marks a 4% year-over-year rise. The company anticipates full-year revenue growth of 6.6% to 7.3%, with Diagnostics expected to grow by 7.2% to 7.8%. Biopharma revenue is projected at 4.7% to 5.6%. Notably, cost-saving initiatives are on track to deliver $100 million to $125 million in savings. A 2.4x net debt to trailing EBITDA ratio reflects financial positioning for future growth through strategic acquisitions.
What is Earnings Call?
LH Profitability Score
Profitability Due Diligence
Laboratory Corporation of America Holdings's profitability score is 50/100. The higher the profitability score, the more profitable the company is.
Score
Laboratory Corporation of America Holdings's profitability score is 50/100. The higher the profitability score, the more profitable the company is.
LH Solvency Score
Solvency Due Diligence
Laboratory Corporation of America Holdings's solvency score is 46/100. The higher the solvency score, the more solvent the company is.
Score
Laboratory Corporation of America Holdings's solvency score is 46/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
LH Price Targets Summary
Laboratory Corporation of America Holdings
According to Wall Street analysts, the average 1-year price target for LH is 269.01 USD with a low forecast of 233.31 USD and a high forecast of 307.65 USD.
Dividends
Current shareholder yield for LH is .
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
Profile
Country
Industry
Market Cap
Dividend Yield
Description
Laboratory Corp. of America Holdings operates as a life sciences company, which engages in the provision of vital information to help health professionals make clear and confident decisions. The company is headquartered in Burlington, North Carolina and currently employs 75,500 full-time employees. The Company’s business segments include Labcorp Diagnostics (Dx) and Labcorp Drug Development (DD). Through its Dx and DD segments, the Company provides diagnostic, drug development and technology enabled solutions. The firm also supports clinical trial activity in approximately 100 countries through its industry central laboratory, preclinical, and clinical development businesses. Dx segment operates through a network of patient service centers, branches, rapid response laboratories, primary laboratories, and specialty laboratories. DD segment, which operates on a global scale. The firm serves a range of customers, including doctors, hospitals, pharmaceutical companies, researchers, governmental agencies, physicians and other healthcare providers. The company also helps in delivering non-clinical testing services.
Contact
IPO
Employees
Officers
The intrinsic value of one LH stock under the Base Case scenario is 259.89 USD.
Compared to the current market price of 239.67 USD, Laboratory Corporation of America Holdings is Undervalued by 8%.